Coleman R, Rubens D. The clinical course of bone metastasis from breast cancer. Br J Cancer 1987; 55: 61–66.
Yoneda T, Michigami T, Yi B. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev 1999; 25: 293–299.
Senaratne S, Pirianov G, Mansi J. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459–1468.
Hiraga T, Williams P, Mundy G. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastasis. Cancer Res 2001; 61: 4418–4424.
Mundy G, Chen D, Oyajobi B. Bone Remodeling. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th Edition. Philadelphia: Lippincott, Williams and Wilkins, 2003: pp. 46–58.
Canalis E. Regulation of bone remodeling. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 3rd edition.New York: Lippincott-Raven; 1996: pp. 29–34.
Guise T, Yin J, Taylor S. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98: 1544–1549.
Kakonen S, Mundy G. Mechanisms of osteolytic bone metastasis in breast carcinoma. Cancer 2003; 97 (Suppl 3): 834–839.
Grano M, Mori G, Minielli V. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. Biochem Biophys Res Commun 2000; 270: 1097–1100.
Taube T, Elomaa I, Blomqvist C. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994; 15: 161–166.
Yin J, Selander K, Chirgwin J. TGF-(beta) signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastasis development. J Clin Invest 1999; 103: 197–206.
Brown J, Thomson C, Ellis S, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003; 89: 2031–2037.
Ali S, Demers L, Leitzel K, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 2004; 15: 455–459.
Costa L, Demers L, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastasis status. J Clin Oncol 2002; 20 (3): 850–856.
Vinholes J, Guo C, Purohit O. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996; 73 (9): 1089–1095.
Lipton A, Demers L, Curley E. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998; 34 (13): 2021–2026.
Hortobagyi G, Theriault R, Porter L. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. New Engl J Med 1996; 335: 1785–1791.
Lipton A. Bisphosphonates and breast cancer. Cancer 1997; 80: 1668–1673.
Paterson A, Powles T, Kanis T. Double-blind controlled trial of oral clodronate in patients with bone metastasis from breast cancer. J Clin Oncol 1993; 11: 59–65.
Rosen L, Gordon D, Kaminski M. Zoledronic acid versus pamidronate in the treatment of skeletal metastasis in patients with breast cancer or osteolytic lesions in multiple myeloma. Cancer J 2001; 7: 377–387.
Rosen L, Gordon D, Dugan W. Zoledronic acid is superior to pamidronate for the treatment of bone metastasis in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100 (1): 36–43.
Body J, Diel I, Lichinitser M. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasis. Ann Oncol 2003; 14: 1399–1405.
Body J, Diel I, Lichinitser M. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo controlled phase III studies. Br J Cancer 2004; 90 (6): 1133–1137.
Powles TJ, Paterson S, Kanis J, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20 (15): 3219–3224.
Diel I, Solomayer E, Costa S, et al. Reduction in new metastasis in breast cancer with adjuvent clodronate treatment. New Engl J Med 1998; 339 (6): 357–363.
Jaschke A, Bastert G, Solomayer E, Costa S, Schuetz F, Diel I. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastasis to bone marrow – a longtime follow-up. [Abstract 529]. J Clin Oncol 2004; 22 (14S).
Saarto T, Blomqvist C, Virkkunen P. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastasis in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19 (1): 10–17.
Saarto T, Vehmanen C, Blomqvist C, Elomaa I. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. [Abstract 527]. J Clin Oncol 2004; 22 (14S)..
Jagadev S, Coleman R, Shipman C. The bisphosphonate zoledronic acid induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126–1134.
Wood J, Schnell C, Green J. Zoledronic acid (zometa), a potent inhibitor of bone resorption, inhibits proliferation and induces apoptosis in endothelial cell in vitro and is anti-angiogenic in a murine growth factor implant model. [Abstract 2620]. Proc Am Soc Clin Oncol 2000; 19: 664.
Wood J, Bonjean K, Ruetz S. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Therap 2002; 302 (3): 1055–1061.